Evaluating the Cost of Genomic Testing for Biomarker-Driven Therapies in Oncology
The insights provided by this calculator demonstrate lower costs using NGS compared with SGT for many malignancies, which suggests that opportunities exist for the expanded use of NGS in routine clinical practice for molecular profiling of patients with cancer.
Authors
- Yogesh Punekar (ORCID: https://orcid.org/0000-0002-7531-1319)
- Jamie Partridge Grossman (ORCID: https://orcid.org/0000-0001-9358-8971)
- Zhuofan Yan
- Magdalene Crabbe
- Elizabeth A. Sheppard
Institutions
- Bayer (United States) (US)
- Universidade do Porto (PT)
- The Francis Crick Institute (GB)
- IQVIA (United Kingdom) (GB)
- DC Cancer Consortium (US)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1007/s40487-026-00416-z
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00